Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ4796 is an oral active fusion inhibitor of the influenza virus, by inhibiting hemagglutinin (HA)-mediated fusion to neutralizing the influenza A group 1 virus. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 15,000 | 8-10周 | ||
50 mg | ¥ 19,800 | 8-10周 | ||
100 mg | ¥ 25,500 | 8-10周 |
产品描述 | JNJ4796 is an oral active fusion inhibitor of the influenza virus, by inhibiting hemagglutinin (HA)-mediated fusion to neutralizing the influenza A group 1 virus. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs). |
靶点活性 | H1/Cal:66 nM(EC50), H1/PR8:22 nM(EC50), H5/Viet:3.24 μM(EC50), H1/Bris:(EC50)12 nM, H1/SI06:13 nM(EC50), H5/H97:449 nM(EC50), H1/NCa:38 nM(EC50) |
体外活性 | The mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA, like bnAb CR6261. That triggers the fusion of the viral and endosomal membranes and the release of the viral genome into the host cell[1]. |
体内活性 | JNJ4796(50 and 10 mg/kg; twice daily) treatment, initiated one day before the challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved. JNJ4796 (p.o.) protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Oral doses of JNJ4796 cause dose-dependent efficacy after a sublethal viral challenge (LD90), with twice-daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1]. |
分子量 | 537.57 |
分子式 | C28H27N9O3 |
CAS No. | 2241664-16-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JNJ4796 2241664-16-2 Others JNJ-4796 JNJ 4796 Inhibitor inhibitor inhibit